Jess Hadley, community pharmacist and Professional Officer at PDL[/caption]
Peter Guthrey, Senior Pharmacist – Strategic Policy at PSA[/caption]
Professor Margie Danchin[/caption]
Dr Peter Tenni[/caption]
How should we deprescribe gabapentinoids, according to the Maudsley Deprescribing Guidelines[/caption]
The pain of uncertainty: Managing pain without codeine
With over-the-counter (OTC) codeine products being upscheduled, pharmacists and pharmacy staff need to review and understand every patient’s pain. In doing so, there’s an...
Training for Health Care Homes program
Community pharmacists working within the Health Care Homes (HCH) model will have access to extensive training from October, to develop their skills in collaborative...
A first line treatment option for cows’ milk allergy
Cows’ milk allergy (CMA) is one of the most common causes of food allergy in babies, affecting 1 in 50 Australian infants.1 As first...
GP Pharmacists change views on pharmacy scope of care
Having a pharmacist in a general practice can be a powerful tool for changing other healthcare practitioners' attitudes towards pharmacy scope of care, a...
Complementary medicines: Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterised by joint inflammation. The immune system attacks the tissue lining the joints (synovial membrane), causing...
Overprescribing of psychotropics for adults with autism
Adults on the autism spectrum are often prescribed psychotropic medication to manage behaviour, despite limited evidence to support this practice, a new report has...
